All-new research in dermatology is available now – take a look at this month’s new and exclusive content on JDDonline.com:
- In a multicenter clinical study, investigators conduct an analysis of data on the Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
-
Authors evaluate Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia in a retrospective chart review of TA patients treated with ILK at an academic dermatology clinic.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
- The IL-17 pathway plays a crucial role in the immunopathogenesis and development of psoriasis in Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
-
A Survey of Dermatologists’ Preparedness for Natural and Manmade Disasters examines whether the dermatology field has advanced in its bioterrorism preparedness since a 2003 survey revealed 88% of dermatologists felt unprepared to respond to a biological attack.
View all February JDD content, including editor’s picks, supplements, CME activities, case reports, and more!
Read Now
You May Also Like
From the Vault: Novel Strategy for Strengthening Dermatoporotic Skin by Managing Cellular Senescence
Microdosed Actives Target Dermal Senescence - A Surprising Lab Advance That Could Reshape Dermatoporosis Care Dermatoporosis —age‑related thinning and fragility of the skin driven by fibroblast dysfunction, ECM breakdown, and…
Increased Risk of Subcutaneous Nodules and Lipomas Following Influenza Vaccination: A Multicenter TriNetX Cohort Study
Influenza Vaccination and Arm Nodules: Uncovering a Hidden Risk A large propensity-matched cohort study using TriNetX data found that intramuscular influenza vaccination carries a 32% higher risk of developing subcutaneous…
